on GENOWAY (EPA:ALGEN)
Solid half-year results for genOway despite declining revenue
GenOway has published its 2025 half-year results, showing an EBITDA margin of 16.9%, above the 15% profitability threshold of its ROUTE50+ strategic plan. Although revenue declined by 10% to €9.6 million, the company maintains a stable financial position.
Investments increased to €8.8 million, with a focus on innovation and production expansion. Operating profit was €0.1 million lower than the previous year. Despite this, genOway remains optimistic about a return to growth in the fourth quarter, supported by a commercial reorganization and projected cost savings.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENOWAY news